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Although anxiety is one of the most frequent symptoms of Parkinson’s disease (PD), only a few clinical tools can eﬃciently and
reliably detect its presence. The aim of the present study was to validate the Hungarian patient-rated version of Parkinson
Anxiety Scale (PAS). A total of 190 PD patients were enrolled into the clinimetric validation phase of the study and another 590
participated in the cross-sectional screening phase. The presence of anxiety disorder was diagnosed based on the Diagnostic and
Statistical Manual of Mental Disorders criteria. The cutoﬀ value for PAS which best discriminated the presence of anxiety from
the absence was 12.5 points (sensitivity of 88.6%, speciﬁcity of 79.9). The area under the curve was 0.847 whereas the ROC
analysis yielded the statistical signiﬁcance level (p < 0 001). The optimal threshold values for mild (Hoehn and Yahr Stage, HYS
1 and 2), moderate (HYS 3), and severe (HYS 4 and 5) disease stages were 10.5, 12.5, and 13.5 points, respectively. Based on the
general threshold anxiety occurred in 35.8% of the patients (persistent anxiety: 29.2%, episodic anxiety: 20.7%, and avoidant
anxiety disorder: 16.8%). We demonstrate that the PAS is a valid, highly reliable, and sensitive tool for assessing anxiety.
1. Introduction
Among the nonmotor symptoms of Parkinson’s disease
(PD), the aﬀective problems have utmost importance.
According to epidemiological studies, the frequency of anxi-
ety disorders is higher than that of depressive problems being
between 25–49% [1, 2]. The spectrum of anxiety is extremely
wide including panic attacks, agoraphobia without panic dis-
order, social phobia, and generalized anxiety disorder.
Besides the general problems of anxiety, PD patients fre-
quently experience disease-speciﬁc symptomatology includ-
ing distress, worry, fear, agitation, embarrassment, and
social withdrawal due to motor symptoms and complications
of antiparkinsonian medication [3, 4]. Besides producing
immense suﬀering, anxiety has a serious impact on the daily
living and health-related quality of life (HRQoL) [5].
In the clinical setup, reliable and highly sensitive tools are
required to identify anxiety problems and monitor the
therapeutic response. Commonly applied instruments, such
as Hamilton Anxiety Rating Scale (HAM-A), the Beck Anx-
iety Inventory, and the Hospital Anxiety and Depression
Scale, have unsatisfactory discriminating abilities [6]. With
the help of The Michael J. Fox Foundation, the Parkinson
Anxiety Scale (PAS) was recently developed and validated
to overcome the limitation of the abovementioned anxiety
scales and to provide a license-free clinical and research tool
for the PD population [7].
The PAS is a 12-item tool which can be either rated by a
trained professional (observer version) or by the patients
themselves (patient-rated version). The PAS make up three
diﬀerent subscales describing the persistent anxiety (5 items),
episodic anxiety (4 items), and avoidance behavior (3 items)
[7]. Each item can be scored on a 5-point Likert scale, with
“0” meaning “not or never” and “4” meaning “severe or
almost always” implying a maximum of total score of 48
points. According to its developers, the assessment of the
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self-rated version can be completed in less than 2 minutes,
whereas the observer-rated version may take up to 5 minutes.
Based on a multinational, multicenter, and cross-sectional
validation study enrolling 360 PD patients, the PAS had
better clinimetric properties than any other existing scale
making it a brief and nevertheless valid and highly reli-
able tool.
The PAS scale was originally developed in four languages
simultaneously (English, Spanish, French, and Dutch) and
subsequently translated into Italian [8]. Since the prevalence
and perceived diﬃculties associated with anxiety diﬀer
among cultures, the cross-cultural validation of the PAS
is clearly needed. Because Hungarian is a Finno-Ugric
language originating from the Uralic language family vastly
diﬀerent from the Anglo-Saxon and Latin languages, we
aimed to validate the Hungarian version of the PAS. Sub-
sequently, we utilized this Hungarian version of PAS
scale for determining the prevalence and severity of anx-
iety in a large pool of Hungarian subjects with PD in a
cross-sectional study.
2. Materials and Methods
2.1. Patients. While in the validation part of the study, 190
consecutive patients fulﬁlling the clinical criteria for PD were
enrolled, another 590 PD subjects participated in the subse-
quent part assessing the prevalence of anxiety. Each subject
gave written informed consent in accordance with the ethical
approval of the Regional and Institutional Ethical Committee
of the University of Pécs (5624/2015), and subsequently they
were examined by a neurologist specializing in movement
disorders. Besides recording demographic data (age, sex,
and level of education), disease-speciﬁc data were noted
(age at onset; disease duration; the presence of motor compli-
cations; duration of ﬂuctuation in years; type of PD, being
either tremor dominant, akinetic rigid, or mixed type; and
antiparkinsonian medication). Patients were evaluated in
ON state while receiving their usual antiparkinsonian and
other medications, and subsequently levodopa equivalent
dosage (LED) calculations were performed [9].
2.2. Validation of the Hungarian Parkinson Anxiety Scale.
Two native Hungarian speakers ﬂuent in English translated
independently the PAS into Hungarian, and an English-
speaking psychologist back-translated the PAS into English.
Subsequently, the original and the back-translated versions
were compared and any discrepancies were ﬁxed to achieve
the ﬁrst Hungarian patient-rated and observer-rated PAS.
Cognitive debrieﬁng was applied on 25 patients before ﬁeld
testing.
The self-rated version of PAS was administered to 190
consecutive PD patients. Exclusion criteria for participation
were the following:
(1) Clinical diagnosis of PD in accordance with the UK
Brain Bank criteria could not be met [10]
(2) Presence of major neurocognitive disorder in accor-
dance with the Diagnostic and Statistical Manual of
Mental Disorders (Fifth edition, DSM-5) criteria [11]
(3) The presence of any neurological or psychiatric
condition possibly interfering the study
2.3. Neurological and Neuropsychological Assessments. The
severity of PD-related symptoms was globally assessed by
the Hungarian-validated version of the MDS-UPDRS [12,
13]. The recently published MDS-UPDRS is a validated scale
to assess nonmotor (nM-EDL, Part I) and motor experiences
of daily living (M-EDL, Part II), motor examination (ME,
Part III), and motor complications (MC, Part IV) [13]. As a
part of the MDS-UPDRS, the Hoehn and Yahr Scale (HYS)
was also taken to detect the overall severity of PD. Disease
severity was categorized as mild (HYS 1 and 2), moderate
(HYS 3), and severe (HYS 4 and 5) [14, 15].
The nM-EDL part of theMDS-UPDRS has items evaluat-
ing the presence and severity of 13 NMS including depres-
sion and anxiety [13]. These items are intended to serve as
screening tools for the presence of these nonmotor symp-
toms [16]. To assess nonmotor symptoms globally, the Non-
motor Symptoms Scale (NMSS) [17, 18] was also included.
This scale is obtained by trained professionals and capable
of simultaneously capturing the severity and frequency of
30 nonmotor symptoms typical for PD. Severity of depres-
sion was assessed by the Hungarian-validated versions of
the Montgomery Depression Scale (MADRS) [19] and the
Beck Depression Inventory; whereas, the severity of anxiety
was measured by the Hamilton Anxiety Scale (HAM-A)
[20] and the PAS, and apathy was rated by the Lille Apathy
Rating Scale (LARS) [21].
Patients were screened for the presence of mild andmajor
neurocognitive disorders by validated neurocognitive tests
[22] (Montreal Cognitive Assessment, cutoﬀ scores <23.5
and <20.5, respectively, and Mattis Dementia Rating Scale,
cutoﬀ scores <139.5 and <132.5 points, resp.) [23, 24].
Health-related quality of life (HRQoL) was measured by the
Hungarian-validated version of the disease-speciﬁc PDQ-39
Summary Index (PDQ-39 SI) [25, 26]. Subsequently, the
presence of anxiety in accordance with the DSM-5 criteria
[11] was assessed by a trained neuropsychiatrist in the
validation phase.
2.4. Statistical Analysis. For variables following the normal
distribution (e.g., age, disease duration), means± standard
deviations (SD) were calculated. Data quality was deﬁned as
the proportion of computable data. The criterion for an
acceptable amount of missing data is <10% [27]. For accept-
ability, the ﬂoor and ceiling eﬀect should be kept <15% [28],
and the skewness should range between −1 and +1 [29].
Before the structure of the scale was explored by a fac-
tor analysis, the value of Kaiser-Meyer-Olkin measure of
sampling accuracy (KMO) was calculated. A KMO >0.60
is a minimum requirement; whereas, KMOs >0.90 are
considered as excellent for factor analysis. We accepted
only those factors having an eigenvalue >1 and a Scree test
for factor analysis.
In the clinimetrics, reliability is the overall consistency of
a measure. A measure is said to have a high reliability if it
produces similar results under consistent conditions [30].
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In our study, the internal consistency was evaluated by four
diﬀerent approaches [31]:
(i) Cronbach’s α should be >0.70 [32].
(ii) Corrected item-total correlation should be >0.30 for
each item.
(iii) Item homogeneity coeﬃcient should be >0.30.
(iv) Test-retest properties (Intraclass Correlation Coef-
ﬁcient, ICC should be >0.6) [33]. The retest prop-
erties of the PASwere analyzed on a subset of patients
(n = 89) one day after the initial examination.
The validity of an assessment is the degree to which it
measures what it is supposed to measure. Therefore, it corre-
sponds to how a measurement is well founded and accurately
describes the real world [30]. In our study, the construct
validity was evaluated by three diﬀerent methods:
(i) Convergent validity: convergent validity refers to the
degree to which a measure is correlated with other
measures that it is theoretically predicted to correlate
[30]. The total score and the subscores of PAS were
compared to the “Anxiety” item of MDS-UPDRS
and HAM-A. For correlation, Spearman’s rank
correlation coeﬃcients were calculated. The values
of correlation coeﬃcients (rS) can indicate weak
(0–0.299), moderate (0.300–0.599), and high
(0.600–1.000) association [34].
(ii) Internal validity: the correlation between the
domains (subscales) should not be too low
(rS< 0.300) or too high (rS> 0.700) either [35].
(iii) Divergent validity: divergent validity tests whether
concepts or measurements that are supposed to be
unrelated are, in fact, unrelated [30]. We tested the
discriminative validity of the PAS against apathy
(Lille Apathy Rating Scale), depressive syndromes
(BDI and MADRS), and cognitive functioning
(MoCA) by calculating Spearman rank correlation
coeﬃcients [7].
The precision of the PAS was estimated by the standard
error of measurement (SEM), where the value of SEM should
be less than the half of the standard deviation.
In order to establish a cutoﬀ value for the total score
of the PAS, which can reliably diﬀerentiate PD patients
with and without anxiety, we applied receiver operating
curve (ROC) analysis. Patients were categorized by the
DSM-5 criteria for anxiety disorders. This categorization
served as the state variable and the PAS total score as
the test variable. The best cutoﬀ value was estimated as
the point on the ROC curve closest to the point of (0.1).
It was calculated as the minimum value of the square root
of (1− sensitivity)2 + (1− speciﬁcity)2. Besides, the area
under the curve, speciﬁcity, sensitivity, and positive and
negative likelihood ratios were calculated for the best cut-
oﬀ value. After establishing the optimal threshold for the
whole population, separate cutoﬀ limits were calculated
for the diﬀerent disease severity categories.
All statistical analyses were carried out using IBM SPSS
software package (version 24.0.0.1, IBM Inc., Chicago,
USA). Statistical signiﬁcance level was set to 5%. Because
the SPSS Suite did not have built-in functions for calculat-
ing positive and negative likelihood ratios, we utilized the
syntax available on the IBM website (http://www-01.ibm.
com/support/docview.wss?uid=swg21483380, assessed on
Jan 15, 2013).
2.5. Determining the Prevalence of Anxiety among Hungarian
PD Patients. Utilizing the newly determined cutoﬀ score for
the presence of anxiety, a large pool of PD patients were
screened (n = 590). The presence and severity of anxiety
was assessed by the patient-rated version of PAS.
3. Results
3.1. Validation of the Hungarian Parkinson Anxiety Scale.
The subject population consisted of 190 PD patients without
major neurocognitive disorder, and their clinical characteris-
tics are demonstrated in Table 1. As for the quality of data,
there was no missing data. The skewness of the scale was
within the limit (0.828). Only a few patients had a total score
of 0 on PAS (4.6%) and no one achieved a maximum score;
therefore, the ﬂoor and ceiling eﬀects were acceptable.
The KMO value was suﬃciently high (0.909) to enable a
factor analysis. The Scree test supported a three-factor solu-
tion explaining 67.6% of the variance. Using the Principal
Component Analysis extraction method with Promax rota-
tion, we identiﬁed the same factor structure as it was origi-
nally described.
The value of Cronbach’s α for the total score and
the persistent, episodic, and avoidance domains was
acceptable (0.935, 0.897, 0.828, and 0.724, resp.). All
the items reached the 0.30 threshold value for the
item-total correlation. Item homogeneity index values
were acceptable for all subdomains and the total score
of PAS. The total score of PAS demonstrated high
Spearman’s rank correlation coeﬃcient with both
HAM-A and MDS-UPDRS “Anxiety” item (0.618 and
0.602). The internal validity for the subdomains of PAS
was acceptable (rS values in the range of 0.300–0.700).
The test-retest validity was also acceptable (ICC=0.824). As
far as the discriminative properties were considered, the total
score of PAS had poor correlation with LARS (rho= 0.226,
p < 0 05), MoCA (rho=−0.185, p < 0 05), and moderate cor-
relation with depression (MADRS rho= 0.536, p < 0 05, and
BDI rho= 0.586, p < 0 05, overall population). In patients
without anxiety, the rho values were 0.219 and 0.317 for
MADRS and BDI; whereas, in the presence of anxiety, these
values increased to 0.504 and 0.584, respectively. These dis-
criminant values were similar to those of the original PAS
validation study [7] and the Italian language validation study
[8]. The precision was acceptable for both the domains and
the total score of PAS.
Based on the DSM-5 criteria, 78 patients (41.1%) had an
anxiety disorder. Generalized anxiety was found in 52
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(27.3%), agoraphobia and social phobia in 48 patients
(25.3%), and panic disorder in 31 patients (16.3%).
The cutoﬀ value for PAS which best discriminated the
presence of anxiety from the absence was 12.5 points. There-
fore a PAS score≥ 13 points may suggest the presence of anx-
iety (sensitivity of 88.6%, speciﬁcity of 79.9%, positive
likelihood ratio: 2.64, and negative likelihood ratio: 0.17).
The area under the curve (AUC) was 0.847 whereas the ROC
analysis yielded the statistical signiﬁcance level (p < 0 001).
The optimal threshold values for mild, moderate, and severe
disease stages were slightly diﬀerent (10.5, 12.5, and 13.5
points, resp.). Subsequently, we also calculated the most opti-
mal threshold values for each subscale (Table 2).
3.2. Prevalence of Anxiety among Hungarian PD Patients. In
most cases, it took approximately 2–5 minutes to administer
the scale if the patients completed by themselves. Based on
the general threshold (12.5 points), anxiety occurred in 211
patients (35.8%). While persistent anxiety was found in 172
(29.2%), only 122 patients (20.7%) had episodic anxiety and
another 99 patients (16.8%) had an avoidant anxiety disor-
der. Demographic and disease-speciﬁc data of the PD
patients with and without anxiety are demonstrated in
Table 3. Patients with anxiety had more severe PD-related
symptoms (higher scores on all domains of MDS-UPDRS),
depressive symptoms (BDI andMADRS), worse neurocogni-
tive performance (MDRS and MoCA), and worse HRQoL
(measured by PDQ-39).
4. Discussion
The aim of the present study was to validate the Hungarian
patient-reported version of the PAS by assessing its funda-
mental clinimetric properties and subsequently determining
the prevalence and severity of anxiety among Hungarian
PD patients. After a standardized translation and back-
translation of the scale, we initiated a hospital-based valida-
tion study on a large diversity of patients having disease
severity from minimal to severe. Our results demonstrated
excellent data quality, high reliability and validity, and good
precision. These ﬁndings are consistent with the results of
the original [7] and the Italian [8] validation studies.
The original validation study revealed the cutoﬀ score of
13.5 points for the most optimal discrimination between the
PD patients having and not having an anxiety disorder for
both the patient-reported and observed-rated versions. How-
ever, a considerably smaller threshold (8.5 points) was calcu-
lated in the Italian validation study for the observer-rated
version. This inconsistency was presumably contributed to
some clinical and methodological factors. While the Italian
sample included only patients with early disease stages
(HYS 1 and 2), the original validation study not only had
higher sample size (362 versus 101) but their subjects also
had longer disease duration (10.4 versus 8.3 years), wider
disease spectrum (HYS 1–4), and more pronounced Parkin-
sonian symptoms (UPDRS score: 24.7 versus 13.3 points).
Moreover, the prevalence rate of anxiety disorders diagnosed
by the DSM criteria used as “gold standard” was also dissim-
ilar between the two aforementioned validation studies (27%
versus 38.6%).
Our calculated threshold value (12.5) is much closer to
that of the original validation study (13.5 points).
Acknowledging the conclusions of the Italian validation
study by hypothesizing the role of disease severity in the
diﬀerences of anxiety threshold value, we included PD
Table 1: Demographic and disease-speciﬁc data of the study
population (n = 190) participating in the validation phase.
Mean or
count
Standard deviation or
percentage
Age (years) 65.8 9.8
Sex
Male 110 57.9%
Female 80 42.1%
Education (years) 12.5 3.2
Disease duration (years) 7.2 6.4
Disease duration (years) 7.2 6.4
Type of disease
Tremor dominant 61 32.1%
Akinetic rigid 79 41.6%
Mixed 50 26.3%
Hoehn and Yahr Stage
Mild (1 & 2) 109 57.3%
Moderate (3) 43 22.7%
Severe (4 & 5) 38 20.0%
Levodopa dosage
(in LED mg)
472.8 510.1
Dopamine agonist usage
(in LED mg)
165.8 219.3
Antiparkinson medication
(in LED mg)
677.5 600.6
MDS-UPDRS nM-EDL 13.1 7.5
MDS-UPDRS M-EDL 13.9 9.1
MDS-UPDRS ME 35.0 15.9
MDS-UPDRS MC 4.4 3.4
Nonmotor Symptoms Scale 53.9 38.8
Montreal Cognitive
Assessment
22.7 4.4
Beck Depression Inventory 11.7 8.8
Lille Apathy Rating Scale −22.5 9.5
Hamilton Anxiety Scale 13.1 6.7
Parkinson Anxiety
Scale (Part A)
7.0 4.6
Parkinson Anxiety
Scale (Part B)
2.4 2.9
Parkinson Anxiety
Scale (Part C)
1.9 2.3
Parkinson Anxiety Scale
(total score)
11.3 8.4
LED = levodopa equivalent dosage; MDS-UPDRS =Movement Disorders
Society-sponsored version of Uniﬁed Parkinson’s Disease Rating Scale;
MDS-UPDRS M-EDL =motor experiences of daily living (Part II of
MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily
living (Part I of MDS-UPDRS); SD = standard deviation.
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patients with a high diversity of disease stages (HYS 1–5)
and calculated distinct threshold values for the diﬀerent
disease severity stages.
Based on the obtained cutoﬀ threshold, we identiﬁed the
prevalence of anxiety among Hungarian PD patients of
which 35.8% is in the range of the internationally published
Table 3: Comparison of the clinical proﬁle of the Parkinson’s disease patients (n = 590) with and without anxiety based on the established
Parkinson Anxiety Scale threshold value.
No anxiety (n = 379) Presence of anxiety (n = 211)
Statistics
Mean or count SD or percentage Mean or count SD or percentage
Age (years) 65.8 9.7 65.9 9.9 NS
Disease duration (years) 7.2 6.1 7.2 7.1 NS
Sex
Male 248 65.4% 92 43.6%
p < 0 001
Female 131 34.6% 119 56.4%
Levodopa dosage (in LED mg) 446.7 517.6 517.3 495.0 NS
Dopamine agonist usage (in LED mg) 175.2 212.6 149.7 229.8 NS
Antiparkinson medication
(in LED mg)
659.5 600.4 708.0 601.2 NS
Parkinson Anxiety Scale (total score) 6.1 3.7 20.2 6.6 p < 0 001
Parkinson Anxiety Scale (Part A) 4.3 2.8 11.5 3.2 p < 0 001
Parkinson Anxiety Scale (Part B) 0.9 1.2 5.0 3.1 p < 0 001
Parkinson Anxiety Scale (Part C) 0.8 1.2 3.7 2.7 p < 0 001
Hamilton Anxiety Scale 10.6 5.7 17.3 6.2 p < 0 001
Beck Depression Inventory 7.7 5.8 18.5 8.8 p < 0 001
Montgomery-Asberg Depression Rating Scale 8.9 6.0 16.2 7.2 p < 0 001
Nonmotor Symptoms Scale 40.5 30.0 76.5 41.5 p < 0 001
Montreal Cognitive Assessment 23.2 4.1 21.8 4.7 p < 0 05
Mattis Dementia Rating Scale 135.8 8.0 133.7 10.4 p < 0 05
Lille Apathy Rating Scale −24.1 8.3 −19.8 10.9 p < 0 001
Parkinson’s Disease Questionnaire 16.7 12.2 32.6 16.8 p < 0 001
MDS-UPDRS
nM-EDL
10.4 6.2 17.8 7.2 p < 0 001
MDS-UPDRS
M-EDL
11.8 8.1 17.5 9.6 p < 0 001
MDS-UPDRS ME 33.2 15.4 38.0 16.3 p < 0 001
MDS-UPDRS MC 3.8 3.2 5.3 3.4 p < 0 001
MDS-UPDRS total score 59.2 26.8 78.4 29.6 p < 0 001
Antidepressant usage 72 19.0% 178 84.3% p < 0 001
Anxiolytics usage 87 22.9% 162 76.7% p < 0 001
LED = levodopa equivalent dosage; MDS-UPDRS =Movement Disorders Society-sponsored version of Uniﬁed Parkinson’s Disease Rating Scale; MDS-UPDRS
M-EDL =motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS);
SD = standard deviation.
Table 2: Calculation of the optimal cutoﬀ levels for detecting anxiety based on receiver operating curve analysis.
Scale Clinical correspondence Cutoﬀ Sensitivity Speciﬁcity AUC p value
Total score of PAS Any anxiety disorders 12.5 88.6% 79.9% 0.847 p < 0 001
Persistent anxiety subscale Generalized anxiety disorder 9.5 89.3% 81.2% 0.875 p < 0 001
Episodic anxiety subscale Panic disorder 4.5 92.1% 81.5% 0.921 p < 0 001
Avoidant anxiety subscale Avoidant anxiety disorders 3.5 78.4% 82.4% 0.835 p < 0 001
Anxiety disorders characterized by avoidance are agoraphobia and social phobia (here taken together as avoidant anxiety disorders). ROC= receiver operating
characteristics; AUC= area under the curve; PAS = Parkinson Anxiety Scale.
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range [1, 2]. Similar to previous ﬁndings, we also demon-
strated that the presence of anxiety was associated with worse
motor performance, cognitive performance, and more
severely impaired health-related quality of life [36, 37].
5. Conclusions
The Hungarian patient-rated version of the Parkinson
Anxiety Scale is a valid, highly reliable, and sensitive tool
for assessing the presence and severity of the anxiety symp-
toms. Although our uniform threshold value may eﬃciently
identify patients with anxiety, diﬀerent threshold values
may be utilized for diﬀerent disease stages.
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PAS skála 
 
 
A. Tartós szorongás 
Kérjük, hogy minden kérdésnél kizárólag egy választ jelöljön meg! 
 
Az elmúlt négy hét során milyen mértékben észlelte az alábbi tüneteket? 
 
A.1. Szorongás vagy idegesség érzése  
□  0. Egyáltalán nem vagy sohasem 
□ 1. Igen csekély fokban vagy ritkán 
□ 2. Enyhe fokban vagy néha 
□ 3. Közepes fokban vagy gyakran 
□ 4. Súlyos fokban vagy (szinte) mindig 
 
A.2. Feszültség vagy stressz érzése 
□  0. Egyáltalán nem vagy sohasem 
□ 1. Igen csekély fokban vagy ritkán 
□ 2. Enyhe fokban vagy néha 
□ 3. Közepes fokban vagy gyakran 
□ 4. Súlyos fokban vagy (szinte) mindig 
 
A.3. Nem tud ellazulni 
□  0. Egyáltalán nem vagy sohasem 
□ 1. Igen csekély fokban vagy ritkán 
□ 2. Enyhe fokban vagy néha 
□ 3. Közepes fokban vagy gyakran 
□ 4. Súlyos fokban vagy (szinte) mindig 
 
A.4. Kifejezett aggódás a hétköznapi ügyek miatt 
□  0. Egyáltalán nem vagy sohasem 
□ 1. Igen csekély fokban vagy ritkán 
□ 2. Enyhe fokban vagy néha 
□ 3. Közepes fokban vagy gyakran 
□ 4. Súlyos fokban vagy (szinte) mindig 
 
A.5. Valami rossz, vagy akár a legrosszabb, dolog megtörténésétől való félelem 
□  0. Egyáltalán nem vagy sohasem 
□ 1. Igen csekély fokban vagy ritkán 
□ 2. Enyhe fokban vagy néha 
□ 3. Közepes fokban vagy gyakran 
□ 4. Súlyos fokban vagy (szinte) mindig 
 
 
B. Időszakosan jelentkező szorongás 
Kérjük, hogy minden kérdésnél kizárólag egy választ jelöljön meg! 
 
Az elmúlt négy hét során észlelt –e az alábbi tünetekkel járó rosszullétet? 
 
B.1. Pánik vagy heves félelem  
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
Név:.......................................... 
 
Születés:.................................... 
 
Dátum:...................................... 
 
B.2. Légzési nehezítettség  
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
B.3. Szívdobogásérzés vagy szapora szívverés (mely nem kapcsolatos fizikális megterheléssel vagy cselekvéssel)  
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
B.4. Önuralom elvesztésétől való félelem  
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
 
 
C. Elkerülő magatartás 
Kérjük, hogy minden kérdésnél kizárólag egy választ jelöljön meg! 
 
Az elmúlt négy hétben milyen mértékben érzett félelmet az alábbi helyzetekben vagy kerülte el az alábbi 
helyzeteket? 
 
C.1. Társasági helyezetek (ahol mások is megfigyelhetik és kritizálhatják, úgymint közönség előtt beszélgetés vagy 
ismeretlenekkel történő társalgás)  
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
C.2. Közösségi helyezetek (olyan helyzetek, ahonnan nehéz vagy pedig zavaró lenne elmenekülni, úgymint sorban 
állás alatt, tömegben, hidakon vagy tömegközlekedés során) 
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
C.3. Speciális helyzetek vagy tárgyak (például repülés során, magasban tartozkodás, pókok vagy egyéb állatok 
látványa, tűk vagy a vér látványa) 
□ 0. Sosem 
□ 1. Ritkán 
□ 2. Néha 
□ 3. Gyakran 
□ 4. Szinte mindig 
 
Hivatkozás: Kovács M, Makkos A, Weintraut R, Karádi K, Janszky J, Kovács N. Prevalence Of Anxiety Among 
Hungarian Subjects With Parkinson's Disease. Behav Neurol 2017;2017:1470149   
The Parkinson Anxiety Scale (PAS); English version 
 
A. Persistent anxiety 
Please mark one circle for each item below 
 
In the past four weeks, to what extent did you experience the following symptoms? 
 
A.1. Feeling anxious or nervous 
o Not at all, or never 
o Very mild, or rarely 
o Mild, or sometimes 
o Moderate, or often 
o Severe, or (nearly) always 
 
A.2. Feeling tense or stressed 
o Not at all, or never 
o Very mild, or rarely 
o Mild, or sometimes 
o Moderate, or often 
o Severe, or (nearly) always 
 
A.3. Being unable to relax 
o Not at all, or never 
o Very mild, or rarely 
o Mild, or sometimes 
34 
o Moderate, or often 
o Severe, or (nearly) always 
 
A.4. Excessive worrying about everyday matters 
o Not at all, or never 
o Very mild, or rarely 
o Mild, or sometimes 
o Moderate, or often 
o Severe, or (nearly) always 
 
A.5. Fear of something bad, or even the worst, happening 
o Not at all, or never 
o Very mild, or rarely 
o Mild, or sometimes 
o Moderate, or often 
o Severe, or (nearly) always 
 
 
B. Episodic anxiety 
Please mark one circle for each item below 
 
In the past four weeks, did you experience episodes of the following symptoms? 
 
B.1. Panic or intense fear 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
B.2. Shortness of breath 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
B.3. Heart palpitations or heart beating fast (not related to physical effort or activity) 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
B.4. Fear of losing control 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
 
C. Avoidance behavior 
Please mark one circle for each item below 
 
In the past four weeks, to what extent did you fear or avoid the following situations?  
 
C.1. Social situations (where one may be observed, or evaluated by others, such as speaking in public, or talking to 
unknown people) 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
C.2. Public settings (situations from which it may be difficult or embarrassing to escape, such as queues or lines, 
crowds, bridges, or public 
transportation) 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
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C.3. Specific objects or situations (such as flying, heights, spiders or other animals, needles, or blood) 
o Never 
o Rarely 
o Sometimes 
o Often 
o Nearly always 
 
Source: Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson 
Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014;29(8):1035-1043. 
